Results 71 to 80 of about 170,342 (313)

Current practice and guideline adherence in renal dose adjustment for patients with chronic kidney disease: A systematic review and meta‐analysis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims To quantify prescribing adherence to renal dosing recommendations in adults with chronic kidney disease (CKD; Stage 3 and above) and to evaluate the clinical consequences of non‐adherence. Methods This systematic review and meta‐analysis was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD42025620883).
Hager ElGeed   +7 more
wiley   +1 more source

The significance of ANGPTL3 and ANGPTL4 proteins in the development of dyslipidemia in Type 2 diabetes mellitus

open access: yesJournal of Family Medicine and Primary Care
Background: Dyslipidemia is the leading cause of cardiovascular disease (CVD) in Type 2 diabetes mellitus patients. As a result, it is critical to target and manage the level of atherogenic lipids.
Rik Swarnakar   +6 more
doaj   +1 more source

INSULIN INITIATION IN T2DM

open access: yesJournal of the ASEAN Federation of Endocrine Societies
INTRODUCTIONThe prevalence of diabetes in Malaysia is rising due to urbanization and socioeconomic changes. Despite evidence supporting good glycaemic control, maintaining optimal control remains challenging, with mean HbA1c levels ranging from 7.9% to 8.1%.
Ooi Chuan Ng, Jo-An Ng
openaire   +1 more source

Biological and translational insights from T2DM genetics [PDF]

open access: yes, 2017
Type 2 diabetes mellitus (T2DM) is a major global health challenge. Development of more effective strategies for prevention and therapy depends on an improved understanding of its pathogenetic mechanisms.
Mark I. McCarthy
core   +1 more source

Safety outcomes of antidiabetic medications: A comprehensive review of the EU summaries of product characteristics and international clinical practice guidelines

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Information on the safety profile of antidiabetic medications is essential for informed treatment decisions in type 2 diabetes mellitus. Although this information is available in regulatory documents of individual drugs, a comprehensive overview across all approved antidiabetics is lacking.
David Liang   +5 more
wiley   +1 more source

Genetic variants linked to T2DM risk in Kurdish populations

open access: yes, 2019
Shadi Golsheh,1 Fatemeh Keshavarzi21Department of Biology, Kurdistan Science and Research Branch, Islamic Azad University, Sanandaj, Iran; 2Department of Biology, Sanandaj Branch, Islamic Azad University, Sanandaj, IranBackground: The polymorphisms of ...
Golsheh S, Keshavarzi F
core  

Hypertension in obesity: A focus on individualized pharmacotherapy and the role of body composition, on behalf of the European Society of Hypertension Working Group on Diabetes and Metabolic Risk Factors and Working Group on Lifestyle, Cardiovascular Pharmacotherapy and Adherence

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Hypertension in obesity represents a major global health challenge, closely linked to the global epidemics of obesity, type 2 diabetes and metabolic dysfunction. Excess adiposity contributes to elevated blood pressure through multiple, interrelated mechanisms, including activation of the renin–angiotensin–aldosterone system, sympathetic nervous system ...
Christina Antza   +12 more
wiley   +1 more source

Evaluation of Hypoglycemic and Hypolipidemic Effects of Jamun (Syzygium Cumini) and Paneer Flower (Withania Coagulans) and Comparison with that of Metformin in Rabbit (Oryctolagus Cuniculus): An Experimental Study

open access: yesJournal of Pharmacy and Bioallied Sciences
Introduction: Diabetes mellitus and hyperlipidemia are the leading public health challenges worldwide, with type 2 diabetes (T2DM) representing most cases of diabetes.
Abhishek Gaurav   +3 more
doaj   +1 more source

Pharmacokinetic and pharmacodynamic interaction of enavogliflozin, a sodium‐glucose cotransporter 2 inhibitor, with glimepiride and metformin in healthy participants

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Enavogliflozin, a sodium‐glucose cotransporter 2 inhibitor, is expected to be coadministered with antihyperglycaemic drugs with different mechanisms of action. This study aimed to investigate the pharmacokinetic (PK) and pharmacodynamic (PD) interactions between enavogliflozin, glimepiride and metformin.
Kyungrin Chang   +5 more
wiley   +1 more source

To Investigate the Effect of Dyslipidemia and Metabolic Function in Coronary Heart Disease with Type 2 Diabetes Mellitus—In the Tertiary Care Center. A Study Protocol

open access: yesJournal of Pharmacy and Bioallied Sciences
Introduction: Type 2 DM is the most common type of diabetes and it is characterized by a combination of insulin resistance and relative insulin shortage caused by pancreatic beta cell failure.
Akansha Singh   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy